Patent application EP16153221A (EP), filed 2016-01-28
Publication number: EP3199949A1
Title: METHOD OF DIAGNOSIS AND/OR PROGNOSIS AND/OR PREDICTION OF THERAPEUTIC RESPONSE OF NEOPLASTIC DISEASES
Abstract: [0001]    The invention provides a method of in-vitro determination of diagnosis and/or prognosis and/or prediction of therapeutic response of a neoplastic disease or a pre-neoplastic diasease from a sample taken from a body of a patient, said method comprising a step of determination of presence, and optionally amount, of a peptide containing a 9 amino acid sequence SATVNLTVI, said peptide being optionally post-translationally modified, in said sample, and subsequently a step of making the diagnosis and/or prognosis and/or prediction of therapeutic response. The peptide is a specific marker indicative of the presence of the IGSF5 protein.
IPC codes: A61K  39/    00            A I
G01N  33/   574            A I
Claims: number: 1
text: A method of in-vitro determination of diagnosis and/or prognosis and/or prediction of therapeutic response of a neoplastic disease or a pre-neoplastic disease from a sample taken from a body of a patient, said method comprising a step of determination of presence, and optionally amount, of a peptide indicative of presence of IGSF5, said peptide being optionally post-translationally modified, in said sample, and subsequently a step of making the diagnosis and/or prognosis and/or prediction of therapeutic response.
number: 2
text: The method of in-vitro determination of diagnosis and/or prognosis and/or prediction of therapeutic response of a neoplastic disease or a pre-neoplastic diasease from a sample taken from a body of a patient according to claim 1, said method comprising a step of determination of presence, and optionally amount, of a peptide containing a 9 amino acid sequence SATVNLTVI, said peptide being optionally post-translationally modified, in said sample, and subsequently a step of making the diagnosis and/or prognosis and/or prediction of therapeutic response.
number: 3
text: The method according to claim 1 or 2, wherein the neoplastic disease is an epithelial cancer or melanoma.
number: 4
text: The method according to any one of claims 1 to 3, wherein the sample taken from the body of a patient is a sample of tumor tissue or body fluid, such as urine, cerebrospinal fluid, ascites, effusions, systemic blood, serum or plasma.
number: 5
text: The method according to any one of claims 2 to 3, wherein the peptide contains sequence SATVNLTVIR or SATVNLTVIW.
number: 6
text: The method according to any one of claims 1 to 5, wherein the peptide contains from 9 to 100 amino acids, or from 9 to 70 amino acids, or from 9 to 50 amino acids.
number: 7
text: The method according to any one of claims 1 to 6, wherein a step comprising digestion of proteins in the sample and/or a step of fractionation of the proteins and/or peptides present in the sample or in the digested sample is carried out prior to the step of determination of presence and/or amount of the peptide.
number: 8
text: The method according to any one of claims 1 to 7, wherein making of diagnosis is based on the presence in the sample of the peptide being indicative of presence of a neoplastic disease.
number: 9
text: The method according to any one of claims 1 to 7, wherein making of diagnosis is based on the detection in the sample of the amount of the peptide of the invention above a threshold value being indicative of presence of a neoplastic disease.
number: 10
text: The method according to any one of claims 1 to 7, wherein making of prognosis is based on the correlation of the detected amount of the peptide of the invention with a stage of a neoplastic disease.
number: 11
text: The method according to any one of claims 1 to 7, wherein making of prediction of therapeutic response is based on the correlation of the detected amount of the peptide of the invention with therapeutic response.
number: 12
text: Use of the peptide indicative of presence of IGSF5, said peptide being optionally post-translationally modified, for a method of in-vitro determination of diagnosis and/or prognosis and/or prediction of therapeutic response.
number: 13
text: Use according to claim 12 of the peptide containing a 9 amino acid sequence SATVNLTVI, said peptide being optionally post-translationally modified, for a method of in-vitro determination of diagnosis and/or prognosis and/or prediction of therapeutic response.
number: 14
text: Use of the peptide indicative of presence of IGSF5, said peptide being optionally post-translationally modified, for production of antibodies.
number: 15
text: Use according to claim 14 of the peptide containing a 9 amino acid sequence SATVNLTVI, said peptide being optionally post-translationally modified, for production of antibodies.
Office action: search_report, dated 2017-08-02
Prior art cited: ref_id: - WISNIEWSKI, J. R.; ZOUGMAN, A.; NAGARAJ, N.; MANN, M: "Universal sample preparation method for proteome analysis", NAT. METHODS, vol. 6, 2009, pages 359 - 362
ref_type: npl
severity: background
ref_id: - TIAN, Y.; ZHOU, Y.; ELLIOTT, S.; AEBERSOLD, R.; ZHANG, H.: "Solid-phase extraction of N-linked glycopeptides", NAT. PROTOC, vol. 2, 2007, pages 334 - 339
ref_type: npl
severity: background
ref_id: - ZHANG, Y.; KUANG, M.; ZHANG, L.; YANG, P.; LU, H.: "An accessible protocol for solid-phase extraction of N-linked glycopeptides through reductive amination by amine-functionalized magnetic nanoparticles", ANAL. CHEM., vol. 85, 2013, pages 5535 - 5541
ref_type: npl
severity: background
ref_id: WO2013006495A2
ref_type: patent
severity: background
ref_id: WO2014205555A1
ref_type: patent
severity: background
ref_id: - ALEXANDRA BRIGGS ET AL: "Abstract 1521: Expression of the tight junctions protein IGSF5 in the colorectal adenoma-carcinoma sequence", CANCER RESEARCH, vol. 72, no. 8 Supplement, 15 April 2012 (2012-04-15), US, pages 1521 - 1521, XP055277917, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2012-1521
ref_type: npl
severity: background
ref_id: WO2013006495
ref_type: patent
severity: background
ref_id: WO2014205555
ref_type: patent
severity: background
ref_id: - ALEXANDRA BRIGGS ET AL, "Abstract 1521: Expression of the tight junctions protein IGSF5 in the colorectal adenoma-carcinoma sequence", CANCER RESEARCH, US, (20120415), vol. 72, no. 8 Supplement, doi:10.1158/1538-7445.AM2012-1521, ISSN 0008-5472, pages 1521 - 1521, XP055277917 [I] 1-15 * abstract *
ref_type: npl
severity: background
Final disposition: pending (2017-08-02)